The University of Chicago Header Logo

Connection

Loren Joseph to Mitogen-Activated Protein Kinase Kinases

Back to Details
This is a "connection" page, showing publications Loren Joseph has written about Mitogen-Activated Protein Kinase Kinases.
Loren Joseph
Connection Strength
0.108
Mitogen-Activated Protein Kinase Kinases
  1. Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial. Clin Cancer Res. 2014 Jan 15; 20(2):490-8.
    View in: PubMed
    Score: 0.108
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.